Corcept Therapeutics Incorporated
NASDAQ:CORTBiotechnology
-$1.96 today
- Market cap
- $7.42B
- Beta
- 0.50
- P/E (TTM)
- 178.2
- EPS (TTM)
- $0.46
Volume 0.74M
Average 1.41M
CORT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Corcept Therapeutics IncorporatedNASDAQ: CORT
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $2.53M (cash outflow) rose 4335.1% year over year, ahead of the +45.0% change in trailing-twelve-month capital expenditures. Sequentially, it rose 1157.7% from the prior quarter. Over 3 fiscal years it compounded at -20.1% a year.
Context
- Capital expenditures amounted to 0.0% of revenue in FY2025, down 0.3 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +4335.1% holds above the trailing-twelve-month pace of +45.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (211K) USD
- Year-over-year change
- +90.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (211K) | +90.3% |
| FY2024 | 2024-12-31 | (2.17M) | -1462.6% |
| FY2023 | 2023-12-31 | (139K) | +66.3% |
| FY2022 | 2022-12-31 | (413K) | +11.9% |
| FY2021 | 2021-12-31 | (469K) | — |
Capital Expenditures vs competitors
How CORT compares with its peers on the latest reported figures
- CORT's LTM Jun 2026 capital expenditures of $2.78M is the 2nd largest of the 3 companies compared; the peer median is $1.67M.
- Its year-over-year change of +45.0% is the lowest of 2, against a peer median of +170.5%.
- Capital expenditures amounts to 0.3% of revenue for CORT.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $3.32M | +170.5% | +63.5% | — |
| LTM Jun 2026 | $2.78M | +45.0% | -20.1% | 0.3% | |
| LTM Mar 2026 | $10K | — | — | — | |
| Peer median (excluding CORT) | $1.67M | +170.5% | +63.5% | — | |
Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 112.51M | 101.42M | 106.14M | 141.21M | 98.17M |
| Depreciation & Amortization | 3.07M | 3.45M | 2.36M | 1.34M | 1.89M |
| Deferred Income Tax | 4.35M | (33.91M) | (29.49M) | (40.19M) | 0 |
| Stock-Based Compensation | 42.93M | 42.44M | 48.94M | 61.35M | 84.5M |
| Change in Working Capital | (57K) | 5.54M | 8.22M | 45.3M | (27.57M) |
| Accounts Receivables | (1.43M) | (17.43M) | (10.07M) | 1.15M | (5.81M) |
| Inventory | 3.44M | 1.2M | 1.27M | 305K | (7.48M) |
| Accounts Payables | (3.6M) | 4.76M | 5.78M | (2.25M) | 25.07M |
| Other Working Capital | 1.52M | 17.02M | 11.24M | 46.09M | (39.34M) |
| Other Non-Cash Items | 5.09M | 1.38M | (9.13M) | (10.94M) | (15M) |
| Operating Cash Flow | 167.89M | 120.32M | 127.04M | 198.07M | 142M |
| Capital Expenditures | (469K) | (413K) | (139K) | (2.17M) | (211K) |
| Acquisitions (Net) | (136.6M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (312.81M) | (355.07M) | (328.75M) | (588.31M) | (319.61M) |
| Sales of Investments | 449.4M | 241.15M | 419.79M | 412.88M | 389.58M |
| Other Investing Activities | 136.6M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 136.13M | (114.33M) | 90.91M | (177.6M) | 69.76M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 9.62M | 0 |
| Common Stock Repurchased | (295.99M) | 0 | (145.43M) | (15.66M) | (245.86M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6.61M) | (17.28M) | (3.3M) | (22.3M) | 25.49M |
| Financing Cash Flow | (302.59M) | (17.28M) | (148.72M) | (28.35M) | (220.37M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 1.44M |
| Net Change in Cash | 1.43M | (11.29M) | 69.22M | (7.89M) | (7.17M) |
| Free Cash Flow | 167.42M | 119.91M | 126.9M | 195.9M | 141.79M |
Corcept Therapeutics Incorporated
NASDAQ:CORT
Intrinsic Alpha fair value
Locked
Current Price
$67.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.